Imunon Inc. Receives Nasdaq Delisting Notice Over Non-Compliance With Minimum Bid Price Requirement

Reuters
15 Jul
Imunon Inc. Receives Nasdaq Delisting Notice Over Non-Compliance With Minimum Bid Price Requirement

Imunon Inc. has announced its receipt of a delisting notice from Nasdaq due to non-compliance with the Minimum Bid Price Requirement, which mandates a minimum bid price of $1.00 per share. This notice follows the company's failure to meet the requirement over a 30 consecutive business day period. Despite requesting a hearing before a Nasdaq Hearing Panel to appeal the delisting determination, Imunon was granted an exception to regain compliance with both the Minimum Bid Price Requirement and the Minimum Stockholders' Equity Requirement. The company faces challenges in regaining compliance and potential complications if its securities are delisted from Nasdaq. Imunon must promptly notify the Panel of any significant developments that could impact its compliance status.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-019541), on July 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10